508 related articles for article (PubMed ID: 26954526)
1. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
Apuri S; Sokol L
Expert Opin Investig Drugs; 2016 Jun; 25(6):687-96. PubMed ID: 26954526
[TBL] [Abstract][Full Text] [Related]
2. Romidepsin for the treatment of non-Hodgkin's lymphoma.
Yazbeck VY; Grant S
Expert Opin Investig Drugs; 2015; 24(7):965-79. PubMed ID: 25936363
[TBL] [Abstract][Full Text] [Related]
3. Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas.
Watanabe T
Expert Opin Investig Drugs; 2010 Sep; 19(9):1113-27. PubMed ID: 20649502
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors in lymphoma.
Copeland A; Buglio D; Younes A
Curr Opin Oncol; 2010 Sep; 22(5):431-6. PubMed ID: 20683267
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
[TBL] [Abstract][Full Text] [Related]
6. Targeting histone deacetylases in T-cell lymphoma.
Moskowitz AJ; Horwitz SM
Leuk Lymphoma; 2017 Jun; 58(6):1306-1319. PubMed ID: 27813438
[TBL] [Abstract][Full Text] [Related]
7. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
Hanikoglu A; Hanikoglu F; Ozben T
Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
[TBL] [Abstract][Full Text] [Related]
8. Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.
Zain J; O'Connor OA
Invest New Drugs; 2010 Dec; 28 Suppl 1(Suppl 1):S58-78. PubMed ID: 21132350
[TBL] [Abstract][Full Text] [Related]
9. Panobinostat for the management of multiple myeloma.
Sivaraj D; Green MM; Gasparetto C
Future Oncol; 2017 Mar; 13(6):477-488. PubMed ID: 27776419
[TBL] [Abstract][Full Text] [Related]
10. Targeting triple negative breast cancer with histone deacetylase inhibitors.
Fedele P; Orlando L; Cinieri S
Expert Opin Investig Drugs; 2017 Nov; 26(11):1199-1206. PubMed ID: 28952409
[TBL] [Abstract][Full Text] [Related]
11. Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL).
Lu G; Jin S; Lin S; Gong Y; Zhang L; Yang J; Mou W; Du J
Clin Epigenetics; 2023 Aug; 15(1):124. PubMed ID: 37533111
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors as anti-neoplastic agents.
Batty N; Malouf GG; Issa JP
Cancer Lett; 2009 Aug; 280(2):192-200. PubMed ID: 19345475
[TBL] [Abstract][Full Text] [Related]
13. Histone Deacetylase Inhibitors as Anticancer Drugs.
Eckschlager T; Plch J; Stiborova M; Hrabeta J
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
[TBL] [Abstract][Full Text] [Related]
14. [Histone deacetylase inhibitors: highlight on epigenetic regulation].
Pécuchet N; Cluzeau T; Thibault C; Mounier N; Vignot S
Bull Cancer; 2010 Aug; 97(8):917-35. PubMed ID: 20483706
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors in the treatment of lymphoma.
Lemoine M; Younes A
Discov Med; 2010 Nov; 10(54):462-70. PubMed ID: 21122478
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitor givinostat: the small-molecule with promising activity against therapeutically challenging haematological malignancies.
Ganai SA
J Chemother; 2016 Aug; 28(4):247-54. PubMed ID: 27121910
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibition restores cisplatin sensitivity of Hodgkin's lymphoma cells.
Kewitz S; Bernig T; Staege MS
Leuk Res; 2012 Jun; 36(6):773-8. PubMed ID: 22424710
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
19. Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
Jimura N; Fujii K; Qiao Z; Tsuchiya R; Yoshimatsu Y; Kondo T; Kanekura T
J Dermatol Sci; 2021 Mar; 101(3):194-201. PubMed ID: 33531202
[TBL] [Abstract][Full Text] [Related]
20. Emerging approaches for histone deacetylase inhibitor drug discovery.
Zwergel C; Valente S; Jacob C; Mai A
Expert Opin Drug Discov; 2015 Jun; 10(6):599-613. PubMed ID: 25895649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
